Nanobodies—single domain antibodies derived from heavy chain variable regions (VHH)—are transforming therapeutic and diagnostic development due to their small size, high stability, and exceptional specificity. Y-Biologics has developed Ymax®-NANO, a human VHH single domain library, designed for high-throughput screening and efficient identification of high-affinity binders.

Ymax®-NANO leverages human germline frameworks to reduce immunogenicity while offering a diverse CDR3 range (8–22 amino acids) and a large library size (10¹⁰ CFU). This platform ensures IP-free deliverables, high human sequence homology (82%), increased productivity (His-tag up to 48 mg/L, Fc-tag up to 100mg/L), and outperforming traditional camelid-based libraries.

The streamlined workflow—from biopanning and monophage ELISA to IgG conversion and affinity characterization—takes approximately 3–5 months and guarantees at least 2–3 unique high-affinity binders per target. Case studies targeting B7-H3, GPRC5D, BCMA, and TROP2 have demonstrated high binder yields and robust ELISA/FACS validation.

Ymax®-NANO is ideally suited for advanced applications including CAR-T therapies, bispecific antibodies, targeted drug delivery, and diagnostics. By eliminating the need for additional humanization steps, it accelerates development while maintaining full antibody ownership for clients. ​